SEC Foi	rm 4 FORM	4 L	INITE	D STAT	ES	SEC					XCHAN	IGE	СС	OMMI	SSIO	N			
to Section 16. Form 4 or Form 5 obligations may continue. See				Washington, D.C. 20549 IT OF CHANGES IN BENEFICIAL OWNI pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									SHIP	OMB	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
1. Name and Address of Reporting Person [*] <u>HO WILLIAM</u> (Last) (First) (Middle) C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE				RA 3. Da	2. Issuer Name and Ticker or Trading Symbol <u>RAPT Therapeutics, Inc.</u> [RAPT] 3. Date of Earliest Transaction (Month/Day/Year) 05/17/2021								(Che	Relationship of Reporting Person(s) to Issuer heck all applicable) Director 10% Owner X Officer (give title Other (specify below) below) Chief Medical Officer					
(Street) SOUTH SAN FRANCISCO CA 94080 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tabl	e I - No	n-Deriva	tive S	Secu	rities	Acq	uired.	Dis	posed of	, or E	Bene	ficial	v Own	ed			
1. Title of Security (Instr. 3) (Month/Day				tion	ion 2A. Deemed Execution Date,			3. 4 Transaction D		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		A) or	5. Amo Securit Benefic Owned	unt of ties cially Following	Forr (D) c	n: Direct	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) (D)	or F	Price		ed ction(s) 3 and 4)			(Instr. 4)
Common Stock 05/17/2					021			S ⁽¹⁾		1,000	L		63,5		3,529		D		
		Ta	ble II -								osed of, convertib				Ownee	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	onversion Date Execution Dat FExercise (Month/Day/Year) if any cerivative		ion Date,	4. Transaction Code (Instr. 8) Code V		5. Nu of Deriv Secu (A) of Dispo of (D) (Instr and 5	rities iired r osed) 7. 3, 4			te	7. Title and Amount of Securities Underlying Derivative Security (In: 3 and 4) Amou or Numi of Title Share		D S (II nstr.	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.

Remarks:

<u>/s/ Rodney Young, Attorney-</u> <u>in-Fact for William Ho</u> 05/1

<u>05/19/2021</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.